Goldman Sachs Remains a Hold on HUTCHMED (HCM)

In a report released today, Paul Choi from Goldman Sachs maintained a Hold rating on HUTCHMED (HCM – Research Report). The company’s...

Related Keywords

Hong Kong ,Bridgebio Pharma ,Paul Choi ,Hutchison China Meditech Ltd ,Goldman Sachs ,Research Report ,China Meditech ,Innovation Platform ,Commercial Platform ,